ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin, Regular, Human

Also written as “Technosphere Insulin”, “inhaled human insulin” and “Human Insulin Inhalation Powder”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Asthma · Diabetes, Gestational, led by 13 companies.

Drug pageInsulin, Regular, Human: every studyMany companies study it; this page follows only the 79 they lead. All 127 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 16, 202179 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mannkindits history only261 open or runningphase 4since Apr 16, 2021Mar 27, 2006Mar 2027phase 2 · NCT07224321
Novo Nordiskits history only190 open or runningphase 4since Aug 10, 2006Jul 17, 2003none ahead
Eli Lilly100 open or runningphase 4since Jan 22, 2013Aug 4, 2005none ahead
Biodelits history only50 open or runningphase 3since Oct 5, 2007Oct 5, 2007none ahead
Pfizerits history only40 open or runningphase 3since Feb 2, 2006Feb 2, 2006none ahead
Dance Biopharmits history only30 open or runningphase 2since Mar 9, 2016Mar 9, 2016none ahead
Halozyme Therapeuticsits history only30 open or runningphase 2since Oct 15, 2008Jun 24, 2008none ahead
Sanofiits history only30 open or runningphase 4since Jun 26, 2012Sep 2, 2010none ahead
Transdermal Delivery Solutionsits history only21 open or runningphase 3since Dec 1, 2021Apr 21, 2021Oct 15, 2027phase 3 · NCT05159453
Diabetes and Glandular Disease Clinicits history only10 open or runningphase 4since Oct 9, 2019Oct 9, 2019none ahead

Also a collaborator on its studies: Langford Research Institute, Insulet, DexCom, Profil Institut für Stoffwechselforschung, Alkermes, WCCT Global and Nektar Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2005First study: phase 3 study in Diabetes Mellitus, Type 1First studyNCT00127634 · 385 enrolled · United States, Belgium, Canada and more
  2. Sep 7, 2005Phase 3 study in Diabetes MellitusNCT00157339 · 299 enrolled · United States, Argentina, Bulgaria and more
  3. May 10, 20062 phase 3 studies in Diabetes Mellitus, Type 2NCT00325364, NCT00330473
  4. Jul 21, 20062 phase 3 studiesNCT00356109, NCT00355849
  5. Oct 19, 2006Phase 3 study in Diabetes Mellitus, Type 2NCT00391209 · 379 enrolled · United States, Argentina, Austria and more
  6. Jun 21, 2007Phase 3 study in Diabetes Mellitus, Type 2NCT00490854 · 129 enrolled · Japan
  7. Jan 22, 2013Phase 4 study in Diabetes Mellitus, Type 2NCT01774968 · 325 enrolled · United States, Puerto Rico
  8. Sep 23, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02561078 · 420 enrolled · United States, Puerto Rico

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02561078Diabetes Mellitus, Type 2 · United States, Puerto Rico3CompletedMay 9, 2017420
NCT01774968Diabetes Mellitus, Type 2 · United States, Puerto Rico4CompletedMay 2014325
NCT00490854Diabetes Mellitus, Type 2 · Japan3CompletedMay 2008129
NCT00391209Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedMay 2008379
NCT00356109Diabetes Mellitus, Type 1 · United States, Argentina, Belgium and more3CompletedMay 2008494
NCT00355849Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more3CompletedJun 2008555
NCT00330473Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedMay 20081,019
NCT00325364Diabetes Mellitus, Type 2 · United States, Brazil, Germany and more3CompletedMay 2008415
NCT00157339Diabetes Mellitus · United States, Argentina, Bulgaria and more3CompletedMay 2008299
NCT00127634Diabetes Mellitus, Type 1 · United States, Belgium, Canada and more3CompletedMay 2008385

How it is read

Names in the registry

  • “Technosphere Insulin”, 13 entries
  • “inhaled human insulin”, 12 entries
  • “Human Insulin Inhalation Powder”, 7 entries
  • “human insulin”, 7 entries
  • “Technosphere® Insulin Inhalation Powder”, 5 entries

Codes read as this program: INH69, INH139, INH208, HR1799.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.